MorphoSys AG announced the appointment of Sung Lee as Chief Financial Officer, effective February 2, 2021. Mr. Lee succeeds Jens Holstein, who stepped down in December 2020, and will lead all corporate finance functions as a member of the Management Board of MorphoSys AG. Sung Lee has more than 20 years of finance leadership experience in biopharmaceutical and technology businesses. Mr. Lee joins MorphoSys from Sangamo Therapeutics Inc., where he served as Chief Financial Officer. Prior to that role, Mr. Lee spent nearly 14 years at Gilead Sciences where he most recently led the global Financial Planning &Analysis and Investor Relations functions.